@prefix orcid: <https://orcid.org/> .
@prefix this: <http://purl.org/np/RAdGMTmExNJhLpAkplkNI5o4ib-vpBJtyfKDpnO0iA6fI> .
@prefix sub: <http://purl.org/np/RAdGMTmExNJhLpAkplkNI5o4ib-vpBJtyfKDpnO0iA6fI#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix ns2: <http://twoc-nlp-database-server-1:8555/solr/predicates/select?q=> .
@prefix ns1: <https://uts.nlm.nih.gov/uts/umls/concept/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix ns3: <http://twoc-nlp-database-server-1:8555/solr/triples/select?q=> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubInfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:assertion prov:wasGeneratedBy "S&T TWOC project version 1" .
  sub:version prov:value 1 .
  rdf:object ns1:C1609165 "tocilizumab" ;
    ns1:C1609931 "siltuximab" ;
    ns1:C3885145 "sarilumab" .
  rdf:predicate ns2:TRIPLE_UID:swcqhjom-TRIPLE-ABSTRACT-5 "include" .
  rdf:subject ns1:C0001617 "corticosteroids" ;
    ns1:C0011777 "dexamethasone" ;
    ns1:C0021760 "IL-6" ;
    ns1:C0243077 "inhibitors" ;
    ns1:C1149241 "IL-6" ;
    ns1:C1334122 "IL-6" ;
    ns1:C1527132 "IL-6" ;
    ns1:C1698754 "IL-6" ;
    ns1:C2983957 "IL-6" ;
    ns1:C3539185 "corticosteroids" ;
    ns1:C3540725 "corticosteroids" ;
    ns1:C3540726 "corticosteroids" ;
    ns1:C3540727 "corticosteroids" .
  rdfs:Triple-UID ns3:TRIPLE_UID:swcqhjom-TRIPLE-ABSTRACT-5 "swcqhjom-TRIPLE-ABSTRACT-5" .
  rdfs:sentence rdfs:label "Currently, there are FDA-approved therapies that attenuate the dysregulated inflammation that occurs in COVID-19 patients, such as dexamethasone or other corticosteroids and IL-6 inhibitors, including sarilumab, tocilizumab, and siltuximab." .
  rdfs:triple rdfs:label "dexamethasone or other corticosteroids and IL-6 inhibitors including sarilumab , tocilizumab , and siltuximab" .
}
sub:provenance {
   sub:assertion prov:generatedAtTime "2021-07-25T21:46:14.949682"^^xsd:dateTime .
}
sub:pubInfo {
   sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB" ;
    npx:hasSignature "T4Tj08g182QZFmw96+spP6sStDsr12QaEMSnYT1hHtRavTWki8ZjVnbeHC6XLB3yzGdHodxLs6Xv4QS7QeklKMOyV9bd+4drm3HuIdDCNpQnlvT+MPOoGkkd5hdAWaQYrFrT0t22NxTQI2/zwZ6BPxu2Ys1UO2O4TecndriGHbM=" ;
    npx:hasSignatureTarget this: .
  this: prov:generatedAtTime "2021-07-25T21:46:14.949682"^^xsd:dateTime ;
    prov:wasAttributedTo orcid:0000-0002-8954-0470 .
}